
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Myopia management is rarely straightforward.
Myopia prevalence continues to rise globally, and with it, clinical pressure on optometrists to intervene earlier and communicate risk more effectively to families. But myopia management is rarely straightforward — questions around when to treat, how to measure success, and how to counsel parents of borderline cases remain common points of uncertainty in practice. In this Q&A, Jeffrey J. Walline, OD, PhD, and Erin Tomiyama, OD, PhD, FAAO, share their clinical approaches to some of the field's most persistent challenges, from selecting the right treatment modality to defining meaningful outcomes for individual patients.






